Semin Thromb Hemost 2022; 48(01): 055-071
DOI: 10.1055/s-0041-1729856
Review Article

Is Lupus Anticoagulant a Significant Feature of COVID-19? A Critical Appraisal of the Literature

1   Department of Haematology, Sydney Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, New South Wales, Australia
2   School of Biomedical Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia
,
3   Cardiac Intensive Care Unit, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
,
4   Section of Clinical Biochemistry, University of Verona, Verona, Italy
› Author Affiliations

Abstract

The term “lupus anticoagulant (LA)” identifies a form of antiphospholipid antibodies (aPLs) causing prolongation of clotting tests in a phospholipid concentration-dependent manner. LA is one of the laboratory criteria identified in patients with antiphospholipid (antibody) syndrome (APS). The presence of LA in patients with APS represents a significant risk factor for both thrombosis and pregnancy morbidity. There have been several reports of similarities between some of the pathophysiological features of COVID-19 and APS, in particular the most severe form, catastrophic APS. There have also been many reports identifying various aPLs, including LA, in COVID-19 patients. Accordingly, a very pertinent question arises: “Is LA a feature of COVID-19 pathology?” In this review, we critically appraise the literature to help answer this question. We conclude that LA positivity is a feature of COVID-19, at least in some patients, and potentially those who are the sickest or have the most severe infection. However, many publications have failed to appropriately consider the many confounders to LA identification, being assessed using clot-based assays such as the dilute Russell viper venom time, the activated partial thromboplastin time (aPTT), and the silica clotting time. First, most patients hospitalized with COVID-19 are placed on anticoagulant therapy, and those with prior histories of thrombosis would possibly present to hospital already on anticoagulant therapy. All anticoagulants, including vitamin K antagonists, heparin (both unfractionated heparin and low-molecular-weight heparin), and direct oral anticoagulants affect these clot-based assays. Second, C-reactive protein (CRP) is highly elevated in COVID-19 patients, and also associated with severity. CRP can also lead to false-positive LA, particularly with the aPTT assay. Third, persistence of aPL positivity (including LA) is required to identify APS. Fourth, those at greatest risk of thrombosis due to aPL are those with highest titers or multiple positivity. Most publications either did not identify anticoagulation and/or CRP in their COVID-19 cohorts or did not seem to account for these as possible confounders for LA detection. Most publications did not assess for aPL persistence, and where persistence was checked, LA appeared to represent transient aPL. Finally, high titer aPL or multiple aPL positivity were in the minority of COVID-19 presentations. Thus, at least some of the reported LAs associated with COVID-19 are likely to be false positives, and the relationship between the detected aPL/LA and COVID-19-associated coagulopathy remains to be resolved using larger and better studies.



Publication History

Article published online:
15 June 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
  • 2 Devreese KMJ, Ortel TL, Pengo V, de Laat B. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16 (04) 809-813
  • 3 Molhoek JE, de Groot PG, Urbanus RT. The lupus anticoagulant paradox. Semin Thromb Hemost 2018; 44 (05) 445-452
  • 4 Favaloro EJ, Wong RCW. Antiphospholipid antibody testing for the antiphospholipid syndrome: a synopsis of challenges and recent guidelines. Pathology 2014; 46 (06) 481-495
  • 5 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101 (05) 1827-1832
  • 6 Lippi G, Sanchis-Gomar F, Favaloro EJ, Lavie CJ, Henry BM. Coronavirus disease 2019-associated coagulopathy. Mayo Clin Proc 2021; 96 (01) 203-217
  • 7 Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Semin Thromb Hemost 2020; 46 (07) 763-771
  • 8 Jenner WJ, Kanji R, Mirsadraee S. et al. Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review. J Thromb Thrombolysis 2021; 51 (03) 595-607
  • 9 Uaprasert N, Moonla C, Sosothikul D, Rojnuckarin P, Chiasakul T. Systemic coagulopathy in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Clin Appl Thromb Hemost 2021; 27: 1076029620987629
  • 10 Carsana L, Sonzogni A, Nasr A. et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis 2020; 20 (10) 1135-1140
  • 11 Wichmann D, Sperhake JP, Lütgehetmann M. et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med 2020; 173 (04) 268-277
  • 12 Bradley BT, Maioli H, Johnston R. et al. Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series. Lancet 2020; 396 (10247): 320-332
  • 13 Varga Z, Flammer AJ, Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395 (10234): 1417-1418
  • 14 Mendoza-Pinto C, Escárcega RO, García-Carrasco M, Bailey DJO, Gálvez-Romero JL, Cervera R. Viral infections and their relationship with catastrophic antiphospholipid syndrome: a possible pathogenic mechanism of severe COVID-19 thrombotic complications. J Intern Med 2020; 288 (06) 737-739
  • 15 El Hasbani G, Taher AT, Jawad A, Uthman I. COVID-19, antiphospholipid antibodies, and catastrophic antiphospholipid syndrome: a possible association?. Clin Med Insights Arthritis Musculoskelet Disord 2020; 13: 1179544120978667
  • 16 Previtali G, Seghezzi M, Moioli V. et al. The pathogenesis of thromboembolic disease in covid-19 patients: Could be a catastrophic antiphospholipid syndrome?. Thromb Res 2020; 194: 192-194
  • 17 Zhang Y, Xiao M, Zhang S. et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 2020; 382 (17) e38
  • 18 Metjian A, Lim W. ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis?. Hematology (Am Soc Hematol Educ Program) 2009; 247-249
  • 19 Mustonen P, Lehtonen KV, Javela K, Puurunen M. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study. Lupus 2014; 23 (14) 1468-1476
  • 20 Pengo V, Ruffatti A, Legnani C. et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011; 118 (17) 4714-4718
  • 21 Yelnik CM, Urbanski G, Drumez E. et al. Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. Lupus 2017; 26 (02) 163-169
  • 22 Larsen JB, Hvas AM. Predictive value of whole blood and plasma coagulation tests for intra- and postoperative bleeding risk: a systematic review. Semin Thromb Hemost 2017; 43 (07) 772-805
  • 23 Devreese KMJ, de Groot PG, de Laat B. et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost 2020; 18 (11) 2828-2839
  • 24 Exner T, Triplett DA, Taberner D, Machin SJ. SSC Subcommittee for the Standardization of Lupus Anticoagulants. Guidelines for testing and revised criteria for lupus anticoagulants. Thromb Haemost 1991; 65 (03) 320-322
  • 25 Pengo V, Tripodi A, Reber G. et al; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7 (10) 1737-1740
  • 26 Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012; 157 (01) 47-58
  • 27 Ledford-Kraemer M, Moore GW, Bottenus R. et al. Clinical and Laboratory Standards Institute (CLSI). Laboratory Testing for the Lupus Anticoagulant; Approved Guideline. CLSI document H60-A. Wayne, PA: CLSI; 2014
  • 28 Tripodi A, Chantarangkul V. Lupus anticoagulant testing: activated partial thromboplastin time (APTT) and silica clotting time (SCT). Methods Mol Biol 2017; 1646: 177-183
  • 29 Pengo V, Bison E, Banzato A, Zoppellaro G, Jose SP, Denas G. Lupus anticoagulant testing: diluted Russell viper venom time (dRVVT). Methods Mol Biol 2017; 1646: 169-176
  • 30 Favaloro EJ, Lippi G. Interference of direct oral anticoagulants in haemostasis assays: high potential for diagnostic false positives and false negatives. Blood Transfus 2017; 15 (06) 491-494
  • 31 Favaloro EJ, Mohammed S, Curnow J, Pasalic L. Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives. Pathology 2019; 51 (03) 292-300
  • 32 Gosselin RC, Adcock DM, Bates SM. et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 2018; 118 (03) 437-450
  • 33 Favaloro EJ, Pasalic L, Curnow J, Lippi G. Laboratory monitoring or measurement of direct oral anticoagulants (DOACs): advantages, limitations and future challenges. Curr Drug Metab 2017; 18 (07) 598-608
  • 34 Exner T, Rigano J, Favaloro EJ. The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays. Int J Lab Hematol 2020; 42 (Suppl. 01) 41-48
  • 35 COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Accessed March 16, 2021 at: https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
  • 36 Favaloro EJ, Lippi G. Recommendations for minimal laboratory testing panels in patients with COVID-19: potential for prognostic monitoring. Semin Thromb Hemost 2020; 46 (03) 379-382
  • 37 Christensen B, Favaloro EJ, Lippi G, Van Cott EM. Hematology laboratory abnormalities in patients with coronavirus disease 2019 (COVID-19). Semin Thromb Hemost 2020; 46 (07) 845-849
  • 38 Levi M, Thachil J. Coronavirus disease 2019 coagulopathy: disseminated intravascular coagulation and thrombotic microangiopathy-either, neither, or both. Semin Thromb Hemost 2020; 46 (07) 781-784
  • 39 Thachil J, Srivastava A. SARS-2 coronavirus-associated hemostatic lung abnormality in COVID-19: Is it pulmonary thrombosis or pulmonary embolism?. Semin Thromb Hemost 2020; 46 (07) 777-780
  • 40 Schulman S. Coronavirus disease 2019, prothrombotic factors, and venous thromboembolism. Semin Thromb Hemost 2020; 46 (07) 772-776
  • 41 Kwaan HC. Coronavirus disease 2019: the role of the fibrinolytic system from transmission to organ injury and sequelae. Semin Thromb Hemost 2020; 46 (07) 841-844
  • 42 Larsen JB, Pasalic L, Hvas AM. Platelets in coronavirus disease 2019. Semin Thromb Hemost 2020; 46 (07) 823-825
  • 43 Favaloro EJ, Henry BM, Lippi G. Increased VWF and decreased ADAMTS13 in COVID-19: creating a milieu for (micro)thrombosis?. Semin Thromb Hemost 2021; 19 (02) 513-521
  • 44 Yasri S, Wiwanitkit V. COVID-19, antiphospholipid syndrome and thrombosis. Clin Appl Thromb Hemost 2020; 26: 1076029620931927
  • 45 Andina D, Noguera-Morel L, Bascuas-Arribas M. et al. Chilblains in children in the setting of COVID-19 pandemic. Pediatr Dermatol 2020; 37 (03) 406-411
  • 46 Helms J, Tacquard C, Severac F. et al; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020; 46 (06) 1089-1098
  • 47 Bowles L, Platton S, Yartey N. et al. Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N Engl J Med 2020; 383 (03) 288-290
  • 48 Harzallah I, Debliquis A, Drénou B. Lupus anticoagulant is frequent in patients with Covid-19. J Thromb Haemost 2020; 18 (08) 2064-2065
  • 49 Tang N. Response to “lupus anticoagulant is frequent in patients with Covid-19” (JTH-2020-00483). J Thromb Haemost 2020; 18 (08) 2065-2066
  • 50 Gatto M, Perricone C, Tonello M. et al. Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases. Clin Exp Rheumatol 2020; 38 (04) 754-759
  • 51 Siguret V, Voicu S, Neuwirth M. et al. Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?. Thromb Res 2020; 195: 74-76
  • 52 Fan S, Xiao M, Han F. et al. Neurological manifestations in critically ill patients with COVID-19: a retrospective study. Front Neurol 2020; 11: 806
  • 53 Devreese KMJ, Linskens EA, Benoit D, Peperstraete H. Antiphospholipid antibodies in patients with COVID-19: a relevant observation?. J Thromb Haemost 2020; 18 (09) 2191-2201
  • 54 Pineton de Chambrun M, Frere C, Miyara M. et al. High frequency of antiphospholipid antibodies in critically ill COVID-19 patients: a link with hypercoagulability?. J Intern Med 2021; 289 (03) 422-424
  • 55 Reyes Gil M, Barouqa M, Szymanski J, Gonzalez-Lugo JD, Rahman S, Billett HH. Assessment of lupus anticoagulant positivity in patients with coronavirus disease 2019 (COVID-19). JAMA Netw Open 2020; 3 (08) e2017539
  • 56 de Ocáriz XGL, Castro Quismondo N, Vera Guerrero E, Rodríguez Rodríguez M, Ayala Díaz R, Martínez López J. Thrombosis and antiphospholipid antibodies in patients with SARS-COV-2 infection (COVID-19). Int J Lab Hematol 2020; 42 (06) e280-e282
  • 57 Cuenca Saez MA, Gomez-Biezna SL. Immunoglobulin A antiphospholipid antibodies in patients with Chilblain-like lesions during the COVID-19 pandemic. Actas Dermosifiliogr 2021; 112 (03) 290-292
  • 58 Tvito A, Ben-Chetrit E, Zimmerman FS, Asher E, Helviz Y. Lupus anticoagulant in patients with COVID-19. Int J Lab Hematol 2021; 43 (01) e17-e18
  • 59 Ferrari E, Sartre B, Squara F. et al. High prevalence of acquired thrombophilia without prognosis value in patients with coronavirus disease 2019. J Am Heart Assoc 2020; 9 (21) e017773
  • 60 Zhang Y, Cao W, Jiang W. et al. Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients. J Thromb Thrombolysis 2020; 50 (03) 580-586
  • 61 Tan YK, Goh C, Leow AST. et al. COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature. J Thromb Thrombolysis 2020; 50 (03) 587-595
  • 62 Xiao M, Zhang Y, Zhang S. et al. Antiphospholipid antibodies in critically ill patients with COVID-19. Arthritis Rheumatol 2020; 72 (12) 1998-2004
  • 63 Fan BE, Ng J, Chan SSW. et al. COVID-19 associated coagulopathy in critically ill patients: a hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis. J Thromb Thrombolysis 2021; 51: 663-674
  • 64 Gazzaruso C, Mariani G, Ravetto C. et al. Lupus anticoagulant and mortality in patients hospitalized for COVID-19. J Thromb Thrombolysis 2020; •••: 1-7 (ePub ahead of print) DOI: 10.1007/s11239-020-02335-w.
  • 65 Le Joncour A, Frere C, Martin-Toutain I. et al. Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward. Autoimmun Rev 2021; 20 (02) 102729
  • 66 Bauer W, Galtung N, Neuwinger N. et al. A matter of caution: coagulation parameters in COVID-19 do not differ from patients with ruled-out SARS-CoV-2 infection in the emergency department. TH Open 2021; 5 (01) e43-e55
  • 67 Hamadé A, Woehl B, Harzallah I, Talbot M, Tousch J, Jambert L. Antiphospholipid antibodies in patients with coronavirus disease 2019 infection hospitalized in conventional unit. Blood Coagul Fibrinolysis 2021; 32 (02) 73-79
  • 68 Karahan S, Erol K, Yuksel RC, Artan C, Celik I. Antiphospholipid antibodies in COVID-19-associated pneumonia patients in intensive care unit. Mod Rheumatol 2021; •••: 1-10 (ePub ahead of print) DOI: 10.1080/14397595.2021.1892257.
  • 69 Beyrouti R, Adams ME, Benjamin L. et al. Characteristics of ischaemic stroke associated with COVID-19. J Neurol Neurosurg Psychiatry 2020; 91 (08) 889-891
  • 70 Galeano-Valle F, Oblitas CM, Ferreiro-Mazón MM. et al. Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism. Thromb Res 2020; 192: 113-115
  • 71 Devreese KM. Antiphospholipid antibody testing and standardization. Int J Lab Hematol 2014; 36 (03) 352-363
  • 72 Schouwers SM, Delanghe JR, Devreese KM. Lupus anticoagulant (LAC) testing in patients with inflammatory status: Does C-reactive protein interfere with LAC test results?. Thromb Res 2010; 125 (01) 102-104
  • 73 De Kesel PMM, Devreese KMJ. The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false-positive results?. Res Pract Thromb Haemost 2019; 4 (01) 161-168
  • 74 Tripodi A, Cohen H, Devreese KMJ. Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2020; 18 (07) 1569-1575
  • 75 Favaloro EJ, Bonar R, Marsden K. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part II--Lupus anticoagulant. Semin Thromb Hemost 2012; 38 (04) 404-411
  • 76 Abdel-Wahab N, Talathi S, Lopez-Olivo MA, Suarez-Almazor ME. Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis. Lupus 2018; 27 (04) 572-583
  • 77 Abdel-Wahab N, Lopez-Olivo MA, Pinto-Patarroyo GP, Suarez-Almazor ME. Systematic review of case reports of antiphospholipid syndrome following infection. Lupus 2016; 25 (14) 1520-1531
  • 78 Cavalli E, Bramanti A, Ciurleo R. et al. Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: diagnostic and therapeutic perspectives (Review). Int J Mol Med 2020; 46 (03) 903-912
  • 79 Million M, Bardin N, Bessis S. et al. Thrombosis and antiphospholipid antibody syndrome during acute Q fever: a cross-sectional study. Medicine (Baltimore) 2017; 96 (29) e7578
  • 80 Mendoza-Pinto C, García-Carrasco M, Cervera R. Role of infectious diseases in the antiphospholipid syndrome (including its catastrophic variant). Curr Rheumatol Rep 2018; 20 (10) 62
  • 81 Catoggio C, Alvarez-Uría A, Fernandez PL, Cervera R, Espinosa G. Catastrophic antiphospholipid syndrome triggered by fulminant disseminated herpes simplex infection in a patient with systemic lupus erythematosus. Lupus 2012; 21 (12) 1359-1361
  • 82 Favaloro EJ, Gilmore G, Arunachalam S, Mohammed S, Baker R. Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): a comparative study using DOAC Stop and andexanet alfa. Thromb Res 2019; 180: 10-19